TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TransMedics Group (NASDAQ:TMDX) had its price target trimmed by TD Cowen from $175.00 to $120.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on the company. Canaccord Genuity Group reduced their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Oppenheimer decreased their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a research report on Tuesday, October 29th. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Buy” and an average target price of $131.80.

TransMedics Group Trading Up 2.8 %

Shares of TMDX stock opened at $79.34 on Monday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company’s 50-day moving average price is $122.08 and its 200-day moving average price is $138.50. TransMedics Group has a twelve month low of $67.77 and a twelve month high of $177.37. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 82.13 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.12) EPS. As a group, equities analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 12.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,958 shares of company stock worth $5,230,528. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group during the second quarter worth approximately $47,000. USA Financial Formulas acquired a new position in TransMedics Group during the 3rd quarter worth approximately $55,000. Quarry LP grew its holdings in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the period. National Bank of Canada FI increased its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Finally, J.Safra Asset Management Corp increased its holdings in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.